hotspot -WSS

hotspot

author：knowledge 2025-09-27 19:37:14 - browse：638

An effective treatment for Alzheimer’s disease has long been a holy grail in the pharmaceutical industry. In early June, some hope appeared when the FDA agreed that the anti-amyloid antibody lecanemab (to be sold by Eisai as Leqembi) outperformed placebo in trials. It is expected to receive full approval by July 6.

But this may not necessarily be purely good news.

On the latest episode of the “First Opinion Podcast,” physician and professor Jason Karlawish argues that lecanemab and other promising new drugs, such as donanemab, will introduce complicated issues into the field of Alzheimer’s care. These medications require a great deal of testing and patient monitoring, trained physicians, and other resources in a system that is already stretched thin.

“Dr. Karlawish’s dream of reason would be … a training module for physicians to learn the key things they need to learn and then self-assess their comfort with the drug,” Karlawish said. “But that’s Karlawish’s dream of reason in a world that seems increasingly less reasonable sometimes.”

Karlawish is a professor of medicine, medical ethics and health policy, and neurology at the University of Pennsylvania’s Perelman School of Medicine. The conversation is based off his recent First Opinion, “The FDA needs a risk evaluation and mitigation strategy for Alzheimer’s drug lecanemab.“

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Mega Millions jackpot grows to $720 million ahead of Friday's drawing

hotspot

WSS

Hey, doctors: Don't be no

Biden White House, tech companies launch new safeguards around emerging AI technology

Washington Commanders' Dan Snyder ordered to pay NFL $60M following investigation

What the cancer research community can learn from the Covid response

ER docs worry over extreme heat as a 'mass casualty event'

Mega Millions jackpot rises to record $1.55 billion for Tuesday's drawing

leisure time

hotspot

focus

In Memoriam: Notable people who died in 2023

Prosecutors say FTX founder Sam Bankman

Anesthesiologist group: stop taking Ozempic before surgery

Influencer to be charged after chaos erupts in New York City's Union Square

23andMe had bad news about my health. I wish a person had delivered it

Biden White House, tech companies launch new safeguards around emerging AI technology

Virginia high school admissions case could be legal follow

ER docs worry over extreme heat as a 'mass casualty event'

Affirmative action in medical school literally saved lives

A former Republican legislative candidate has been charged for his role in the US Capitol riot

knowledge

2 US Navy sailors arrested for allegedly spying for China

EMA weighs against approval for Mirati's lung cancer drug

Biden, Billy Joel, Elton John lead tributes for Tony Bennett after singer's death at 96

What is artificial intelligence? Experts weigh in

Listen: BridgeBio's big week & Lilly's Alzheimer's data

What the cancer research community can learn from the Covid response

focus

focus

hotspot

hotspot